(NASDAQ: FHTX) Foghorn Therapeutics's forecast annual revenue growth rate of 12.55% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Foghorn Therapeutics's revenue in 2026 is $30,909,000.On average, 12 Wall Street analysts forecast FHTX's revenue for 2026 to be $1,920,764,531, with the lowest FHTX revenue forecast at $0, and the highest FHTX revenue forecast at $2,968,942,673. On average, 12 Wall Street analysts forecast FHTX's revenue for 2027 to be $2,454,212,840, with the lowest FHTX revenue forecast at $1,108,405,264, and the highest FHTX revenue forecast at $4,079,327,232.
In 2028, FHTX is forecast to generate $2,392,967,794 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $4,927,709,670.